Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of Chronic Kidney Disease (CKD) based on eGFR category and albuminuria category per the Kidney Disease: Improving Global Outcomes (KDIGO) criteria
Have been on a maximally tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) for 90 days preceding screening and is expected to remain on a stable regimen through the study
If on additional treatment for CKD, must be on stable dose for at least 90 days before screening.
If diagnosed with Type 2 Diabetes, should be on stable antihyperglycemic treatment for at least 90 days before screening.
You may not be if
Have any one of the following cardiovascular conditions 90 days prior to screening:
* myocardial infarction
* stroke
* hospitalization or urgent visit for heart failure, and
* coronary, carotid, or peripheral artery revascularization.
Have a documented New York Heart Association (NYHA) Class IV heart failure at the time of screening.
Have chronic or intermittent hemodialysis or peritoneal dialysis 90 days prior to screening.
Have acute dialysis or acute kidney injury 90 days prior to screening.
Have a history of a congenital or hereditary kidney disease, polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and nephrotic syndrome
Requires chronic immunosuppression.
Have HbA1c \>8.5% at screening
Have had a transplanted organ or are awaiting an organ transplant
Have a diagnosis or history of malignant disease within 5 years prior to baseline.
